NMDA-Receptor Blockade in Huntington's Chorea
Data Collection
Basal Ganglia Diseases+16
+ Mental Disorders
+ Brain Diseases
Treatment Study
Summary
Study start date: April 1, 1999
Actual date on which the first participant was enrolled.The objective of this study is to evaluate the acute effects of the putative NMDA-receptor antagonist amantadine on chorea of patients with Huntington's disease (HD). Participants in this study will have mild to moderate HD associated with chorea.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.25 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
All patients will carry a diagnosis of Huntington's disease confirmed by DNA testing. Patients will have mild to moderate disease with associated significant chorea. Ability to comply with study requirements and to report on their condition by telephone. Males and females between the ages of 18 and 82. No patients with the presence or history of any medical condition that can reasonably be expected to subject the patient to unwarranted risk. No patients with renal impairment (serum creatinine exceeding the upper limit of normal). No patients with a history of intolerance to previous exposure to amantadine. No patients with an MMSE of less than 18/30. No patients receiving other anti-chorea therapies (such as Haldol). Those receiving other anti-chorea therapies must stop taking these medications for at least 4 weeks prior to the study to be eligible. No pregnant women. Patients must practice effective means of birth control.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, United StatesOpen National Institute of Neurological Disorders and Stroke (NINDS) in Google Maps